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There are conflicting reports of adverse pregnancy outcomes following the administration of 
antiretroviral treatment (ARVs) to HIV-positive pregnant women.  The aim of this study was to assess 
the magnitude of adverse effects of antiretroviral drugs and to underscore their importance in limiting 
adverse pregnancy outcomes in newborns. 
Methods  
The study was a retrospective analysis of medical records of HIV-infected pregnant women who 
received anti-retroviral treatment at the University of Port Harcourt Teaching Hospital between 
January 2010 and December 2013. Data was analyzed using Epi Info Version 7 Statistical Package.  
Proportions, measures of centrality/dispersion as well as measures of association between maternal 
predictors and birth outcomes were computed. The level of significance was set at p≤ 0.05. 
Results 
A total of 290 medical records of women who received anti-retroviral treatment were examined: 
68.3% women commenced antiretroviral treatment before pregnancy, 3.8% started in 2nd trimester of 
pregnancy and 14.1% during labour.  Pregnancy outcomes were as follows: 90.7% were live births; 
92.4% neonates had Apgar scores ≥7 and 90.7% had birth weights of ≥ 2,500 grams.  More than half, 
55.9% had haemoglobin levels ≥ 10g/dl, while 84.8% of them were born full term.  There were only 
9.3% stillbirths and 9.3% low birth weights respectively, and also 15.2% preterm births.  
Conclusion 
The prevalence of adverse pregnancy outcomes in the study was minimal and stresses the value of 
antiretroviral treatment in the prevention of adverse pregnancy outcomes in newborns.  We therefore 
recommend its intensified utilization for maximum impact in reducing adverse pregnancy outcomes.  
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INTRODUCTION 
The human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) have 
remained a disease of public health concern in most developing countries of the world. Globally, 
there are approximately 1.4 million pregnant women living with HIV in low- and middle-income 
countries, 1 while most children infected with HIV acquire it from their mothers during pregnancy, 
labour and delivery and during breastfeeding. 2 For HIV positive mothers, the tendency to have 
poor birth outcomes have been reported to increase approximately 7 times compared to non HIV-
infected mothers. 3 Meanwhile, untreated maternal HIV-infection has also been reported to be 
associated with higher frequency of low birth weight and 5-minutes Apgar score of less than 7. 4  
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HIV prevalence among pregnant women in Nigeria is 3.6%, 5  while a vertical transmission rate of 
3.9% was reported in the south-east geo-political zone of Nigeria.6  Rivers State is one of the 36 
states of the Federation of Nigeria with the highest prevalence of HIV/AIDS, posting a prevalence 
rate of 15.2% among women attending prenatal clinics.5  The World Health Organization (WHO) in 
2009 projected that there was a 15 to 45 percent chance of HIV-infected pregnant women 
transmitting the virus to their children in resource-constrained settings as a result of  limited access 
to anti-retroviral drugs (ARVs).7   The poor Prevention of Mother-to-Child Transmission of HIV 
programme (PMTCT) coverage in Nigeria readily comes into focus as only about 4.7% of the 
prenatal care facilities offer PMTCT services.2  Anti-retroviral drugs given during pregnancy, labour 
or post-partum improve maternal health and survival, and reduce the risk of vertical transmission 
of the virus (HIV).8  Unfortunately, only 27% of pregnant women living with HIV infection 
(PWLHIV) in Nigeria received ARVs in 2011.9 The problem has been repeatedly attributed to long 
standing health systems issues, such as staffing, service accessibility, community-level factors, such 
as stigma, fear of disclosure and lack of partner support.10  All the same, with an increasing number 
of pregnant women worldwide benefiting from an expanding access to antiretroviral treatment, the 
WHO has called for the "virtual elimination" of paediatric HIV infection by countries targeting a 
mother-to-child HIV transmission (MTCT) risk of less than 5%.11    
 
The adverse pregnancy outcomes reported in HIV-positive women include increased rates of 
spontaneous abortion, low birth weight babies, stillbirths, preterm delivery of less than 37 weeks 
gestation, low Apgar Score of less than 7 within 5 minutes, small-for-gestational age, neonatal 
deaths and birth defects.12  HIV-positive pregnant women who received antiretroviral drugs were 
said to have had fewer of these adverse pregnancy outcomes when compared with HIV-positive 
pregnant women who did not.4  While the beneficial effects of antiretroviral therapy on mother-to-
child transmission are indisputable, monitoring antiretroviral therapy in pregnancy has remained a 
priority for achieving minimal adverse pregnancy outcomes.  There are conflicting reports 
however, concerning adverse pregnancy outcomes following the administration of ARVs to HIV-
positive pregnant women.  Some studies have reported that the use of highly active anti-retroviral 
treatment (HAART) in itself might be associated with adverse pregnancy outcomes.  For example, 
birth defects were reported to have occurred when efavirenz, a non-nucleoside reverse 
transcriptase inhibitor (NNRTI) was used as part of the regimen administered to HIV-positive 
pregnant women in early pregnancy. 13 Nevertheless, other researchers found no such 
relationships, but rather the opposite result that antiretroviral drugs reduced the risk of adverse 
birth outcomes. 4 Also, a more recent study also found no evidence of an increased risk of congenital 
abnormality of the central nervous system, such as neural tube defect with first trimester exposure 
to efavirenz. 14    
 
The aim of this study was therefore to assess the magnitude of adverse effects of antiretroviral 
drugs used for the prevention of mother-to-child transmission of HIV on birth outcomes at the 
University of Port Harcourt Teaching Hospital, and to determine the effects of some predictors 
which increase the risk of adverse birth outcomes. This is with a view to further underscore the 
public health importance of antiretroviral drugs in the prevention and control of the HIV epidemic 
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Rivers State is one of the 36 states of Nigeria with the highest prevalence rates of HIV/AIDS 
(15.2%) among women attending antenatal (ANC) clinics.5 The University of Port Harcourt 
Teaching Hospital is an 840-bed capacity hospital that also serves as a treatment centre for 
HIV/AIDS patients in Rivers and other neighbouring states of Imo, Abia, Bayelsa, Akwa Ibom, and 
Delta states.  
 
This study was conducted at the Maternity clinic of the Obstetrics and Gynaecology Department. 
The clinic runs a PMTCT Programme that first commenced in 2002. Before then, HIV-positive 
pregnant women were referred to the Anti-retroviral Clinic (ARV) clinic established in 1998 for 
antiretroviral treatment. The ARV and PMTCT clinics jointly monitor the patients for drug 
compliance and maternal/foetal welfare.  At present, the hospital is being supported by an 
International non-governmental organization, Family Health International (FHI-360), under its 
SIDHAS Project (Strengthening integrated delivery of HIV/AIDS services).  
 
Research Design and Population: 
The study is a retrospective analysis of medical history and pregnancy outcome of HIV-infected 
pregnant women who received PMTCT services at the hospital between January 2010 and 
December 2013 and followed-up till delivery in the hospital.  
 
Inclusion and Exclusion criteria: 
All HIV-infected pregnant women who received PMTCT services from the hospital and who 
remained under care at the hospital until delivery were included, while all HIV-positive pregnant 
women who delivered without being registered for PMTCT services in the hospital were excluded. 
 
Sample Size Determination: 
A minimum sample size of the study (n) was determined using the formula: n = z2pq/d2. The 
computation was based on the study carried out at the University of Benin Teaching Hospital, Benin 
City, Nigeria, by Onakewhor, et al, 4 which compared the pregnancy outcome of HIV-positive 
pregnant women on antiretroviral treatment to that of HIV-positive pregnant women not on anti-
retroviral therapy. In that study, preterm delivery of 25% was the highest birth outcome variable 
among women who did not receive anti-retroviral treatment, and thus informed the basis for the 
determination of the minimum sample size for the study.  
n = required minimum sample size for the study; z = the z-score corresponding to 5% level of 
significance = 1.96; p = prevalence rate of preterm delivery at 0.25 (25%); q = 1 – p    i.e. 1 – 0.25 = 
0.75; d = 5% (precision); n = 1.962 x 0.25 x 0.75/ (0.05)2 = Approx. 288 cases.  Therefore a minimum 
of 288 cases was determined adequate for the validity of the study.   
 
Sampling Technique: 
A total of 16,493 pregnant women received care at the hospital during the period under review 
(between January 2010 and December 2013).  Out of these, 492 were HIV-positive.  Both the 
proportionate stratified and systematic sampling techniques were used to obtain the required 
sample for the study. Using the stratified sampling method proportionate to size, a breakdown of 
the number of records for each of the years under review was determined as shown in Table 1. 
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The systematic random sampling technique was then used to select the stipulated number of 
patient records from the total number of HIV positive records in each year from a randomly 
selected starting point.  A sampling frame (x) was constructed for each year and the sampling 
interval (k), approximately 2, was determined by dividing the study population (N) by the sample 
size (n) i.e.  k=N/n (value of column D/ value of column C).  The sequential order of: x + k, x + 2k, x + 
3k and so on, was then applied to select the desired sample size for each year. That translated to 
selecting every alternate case record for each year. However, eligible case notes without the 
relevant data were rejected and the next with required data was selected.  
 
Data Collection: 
A structured data tool, in line with the objectives of the research was developed and pre-tested to 
ensure that it could retrieve all relevant information from the patients’ records. It contained 
sections on socio-demographic profile of the women, neonatal and maternal characteristics. Each 
folder was identified using the hospital number. Parameters assessed were based on WHO/UNAIDS 
definition of adverse outcome reported in HIV-positive women.12 Some of those included: histories 




All collected data were analyzed using the Epi Info Version 7 Statistical Package. Statistical 
calculations for proportions, measures of centrality/dispersion and measures of association 
between maternal predictors and birth outcomes such as odds ratio, tests of significance were 
computed. Results were presented using frequency tables. A p-value of ≤0.05 was considered 
statistically significant.  
 
Ethical Considerations: 
Ethical approvals for the study were granted by the Ethics and Research Review Board of the 
University of Port Harcourt, Port Harcourt, while approval to conduct the study was obtained from 
the University of Port Harcourt Teaching Hospital.  All information in the patients’ folders, including 
patient identification was treated with utmost confidentiality and all folders were returned to the 




A total of 290 HIV- positive pregnant women were recruited into the study. Those in the age 
bracket of 25 – 29 years constituted the majority, 119 (41.0%), while those in the age bracket 15-19 









2010 4506    107 63   
2011 4824   131 77 
2012 3968 125 73 
2013 3195 129                           75 
Total 16,493                                                 492 288
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years were only two (0.7%).  Their mean age was 29.54 ± 4.65. Of these, 263(90.7%) were married, 
while the rest were single. The majority of the women had secondary level of education, 38 (13.1%) 
and 175 (60.3%) were statutorily employed. The rest were either housewives or students. (Table 2) 
 
Table 2: Socio-economic/demographic characteristics of pregnant women 
Characteristics (n=290) Freq (%) 
 
Age   
15-19 2 (0.7) 
20-24 31(10.7) 
25-29 119 (41.0) 
30-34 92 (31.7) 
35-39 36 (12.4) 
40-49 6 (2.1) 
Marital Status   
Single 27(9.3) 
Married 263(90.7) 
Education Status   
None 2 (0.7) 
Primary Education 38 (13.1) 
Secondary Education 162 (55.9) 
Post-Secondary 88 (30.3) 
Employment Status   
Unemployed 22 (27.6) 
Self-employed 125 (43.1) 
Government employed 50 (17.3) 
Student 35 (12.1) 
Religion (n=284)  
Christianity 280 (98.6) 
Muslim 4 (1.4) 
 
 
Characteristics of the mothers: 
The majority of the women, 287 (99.0%) were positive for both HIV 1 & 2, while only 3 (1.0%) 
tested positive for HIV 1 only. All 290 women had their CD4 counts evaluated: 187 (64.5%) had 
CD4 values more than 350 cells/mm3, while only 34 (11.7%) had CD4 counts less than 200 
cells/mm3. Most of the women, 258 (89.0%) had normal systolic blood pressure values of less than 
140 mm Hg, and 237 (81.7%) had normal diastolic pressure values of less than 90mmHg.  Nearly all 
the ARVs used by the patients were Nucleotide Reverse Transcriptase Inhibitors (NRTIs).  Only one 
patient (0.3%) received efaverenz, a non-nucleotide Reverse Transcriptase Inhibitors (NNRTI). 
Also, none of the antiretroviral drugs contained any Protease Inhibitors. Overall, 198 (68.3%) of the 
pregnant women commenced ART before pregnancy, while only 11 (3.8%) started ART in 2nd 
trimester of the pregnancy. A total of 263 (90.7%) of the deliveries were live births, while 27 
(9.3%) were stillbirths. There were no records of maternal deaths within the immediate 
postpartum period before discharge. Details of maternal characteristics are in Table 3. 
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Table 3: Clinical Characteristics of Mothers  
Characteristics Freq (%) 
 
Parity  
<3 248 (85.5) 
≥3 42 (14.5) 
HIV Type  
1 3 (1.0) 
1&2 287 (99.0) 
Systolic Blood Pressure level   
<140mmHg 258 (89.0) 
≥140mmHg 32 (11.0) 
Diastolic Blood Pressure level   
<90mmHg 237 (81.7) 
≥90mmHg 53 (18.3) 
CD4 count  
Less than200 34(11.7) 
200-350 69 (23.8) 
>350 187 (64.5) 
Names of ART Used  
Efavirenz,tenofovir, lamivudine 1 (0.3) 
Nevirapine, zidovudine, lamivudine 22 (7.6) 
Zidovudine, Lamivudine, Nevirapine 267 (92.1) 
Time of ART Commencement  
<14 weeks 35 (12.1) 
≥14 11 (3.8) 
At Labour 41(14.1) 
During Lactation 4 (1.4) 
Before Pregnancy 198 (68.3) 
Type of Birth  
Singleton 283 (97.6) 
Multiple 7 (2.4) 
Mode of Delivery  
Elective Caeserean Section 84(30.0) 
Emergency Caeserean Section 101 (34.9) 
Spontaneous Vaginal Delivery 105 (36.2) 
Delivery Outcome  
Live birth 263 (90.7) 
Still birth 27 (9.3) 
Survival status after delivery  
Alive 290 (100.0) 
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Characteristics of the newborns: 
Regarding Apgar score ratings; 268 (92.4%) of the newborns had scores ≥7, while only 22 (7.6%) 
had Apgar scores less than 7 at 5 minutes after birth.  On the prevalence of low birth weight (i.e. 
weight less than 2500grams): 263 (90.7%) had birth weights of ≥ 2,500 grams, while only 27 
(9.3%) had low birth weights.  Haemoglobin (Hb) levels of the neonates were as follows: 162 
(55.9%) were above 10g/dl, while 128 (44.1%) had (Hb) levels less than 10g/dl.  Preterm delivery 
(i.e. delivery in less than 37 weeks of pregnancy), occurred among 44 (15.2%) of the neonates, 
while the rest 246 (84.9%) were born full term (≥37 weeks), (Table 4). 
 
Table 4: Birth Outcome of Neonates 
Characteristics Freq (%) 
 
Apgar Score   
<7 at 5 min 22 (7.6) 
≥7 at 5 min  268 (92.4) 
Birth Weight   
<2500 grams 27 (9.3) 
≥2500 grams 263 (90.7) 
Haemoglobin Level   
<10g/dl 128 (44.2) 
≥10g/dl 162 (55.9) 
Preterm   
<37 weeks 44 (15.2) 
≥ 37 weeks  246 (84.8) 
 
The effects of some maternal predictors on birth outcomes:  
There was no significant association between some maternal predictors which increase the risk of 
adverse birth outcomes and the actual result.  The maternal CD4 cell count, haemoglobin level, 
HAART exposure and old age did not reveal any significant adverse association on the Apgar scores, 
birth weights, time of delivery and birth outcome (p > 0.05).  Similarly, there was no adverse 
association between the time of ART commencement and maternal CD4 cell count, Haemoglobin 
level of babies, and their birth weights. However, the timely commencement of ART, before 
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Table 5: The effects of maternal predictors on birth outcomes  
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Pregnancy outcomes following antiretroviral treatment are commonly reported findings in 
scientific literature.  This is because the HIV infection in pregnancy has become the most common 
complication of pregnancy in some developing countries and also a leading cause of maternal 
mortality in some populations in developing countries. 12 These adverse pregnancy outcomes 
include, but not limited to increased rates of spontaneous early abortion, low birth weight babies 
and stillbirths, preterm labour and preterm rupture of membranes. 12, 15, 16   However, the data from 
our study showed that the frequency of occurrence of these adverse birth outcomes was quite 
minimal.  This might be attributed to the early commencement of treatment by most of the women 
and adequacy of monitoring during pregnancy as was postulated by Onakewhor and colleagues in 
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their study in Benin City4. There were neither recorded maternal deaths nor toxicities.  The result 
was in conformity with those of Young et al, 17 in Uganda, which found no relationship between 
adverse pregnancy outcomes and HAART use. It also validates the findings of Onakewhor and 
colleagues in Benin City,4 Nigeria, where untreated HIV mothers had more adverse obstetric and 
perinatal events than those who received HAART treatment. Our results thus support the argument 
that ART can be very useful in the prevention of adverse birth outcomes and the mother-to-child 
transmission of HIV, and hence stabilizing the epidemic in sub-Saharan Africa.  However, we are 
conscious of the fact that ascertaining adverse outcomes based on the methodology of our study 
alone has some obvious limitations, since it was based on retrospective analysis of data.  Other 
environmental and social factors might also have contributed to the observed results.  
 
The maternal factors documented in our study included the maternal CD4 counts, maternal 
haemoglobin levels, HAART exposures, and old age.  Chen et al, in 2012 had reported that maternal 
HIV was significantly associated with stillbirth (SB), preterm delivery (PTD), small-for-gestational 
age (SGA), and neonatal death (NND).16   Similar adverse outcomes were also reported by Olagbuji 
and colleagues in Nigeria in 2010 in a case- control study.18 However, none of these predictors 
showed any risk of relationship with pregnancy outcomes in our study.  The noticeable decrease in 
adverse pregnancy outcome might be related to the early ART commencement and good adherence 
to treatment regimen by most of the HIV-positive women as was documented by by Onakewhor 
and colleagues4. This thus support the evidence that HIV-infected women who were initiated on 
antiretroviral therapy before their pregnancy, not only had significantly decreased risk of mortality, 
but also had better pregnancy outcomes compared with HIV-infected women who were not under 
any medication.19, 4 Therefore, initiating HIV-positive women on antiretroviral therapy as early as 
possible should be considered a vital means of reducing the maternal mortality and other adverse 
maternal outcomes among them. To buttress this point further, a study by Baroncelli and colleagues 
in 2009 on trends in antiretroviral treatment in late pregnancy, observed an insignificant reduction 
in viral load and a reduction in HIV transmission rate of only below 2%, with no significant changes 
in preterm delivery, Apgar score, birth weight, and birth defects.20 
 
The time of ART commencement against variables like CD4 count, Haemoglobin level, birth weight 
and Apgar score showed no significant negative association or outcomes; rather it showed that 
early commencement of ART was likely to improve the Apgar score of newborns at delivery.  The 
finding supports the result obtained by von Linstow and colleagues in 2010 which showed that 
none of the women who received ART before week 22 of pregnancy in their study  transmitted HIV 
to their children.21 
 
Study Limitations: 
The study was first, based on secondary data that were recorded without the objectives of the study 
in focus and therefore had some missing information. This was remedied by ensuring that only case 
notes with requisite data were included in the study.  Second, the HIV status of children through 
early infant diagnosis (EID) could not be established because the facility was not available at the 
hospital during the period under review.   
Conclusion: 
The study underscores the significance of anti-retroviral treatment in the prevention of adverse 
pregnancy outcomes in newborns and recommends their intensified utilization for maximum 
impact in the reduction of adverse pregnancy outcomes in neonates.   
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